Some applications of the presently disclosed subject matter relate generally to analysis of bodily samples, and in particular, to optical density and microscopic measurements that are performed upon blood samples.
In some optics-based methods (e.g., diagnostic, and/or analytic methods), a property of a biological sample, such as a blood sample, is determined by performing an optical measurement. For example, the density of a component (e.g., a count of the component per unit volume) may be determined by counting the component within a microscopic image. Similarly, the concentration and/or density of a component may be measured by performing optical absorption, transmittance, fluorescence, and/or luminescence measurements upon the sample. Typically, the sample is placed into a sample carrier and the measurements are performed with respect to a portion of the sample that is contained within a chamber of the sample carrier. The measurements that are performed upon the portion of the sample that is contained within the chamber of the sample carrier are analyzed in order to determine a property of the sample.
In accordance with some applications of the present invention, a plurality of images of a microscopic imaging field of a blood sample are acquired, each of the images being acquired using respective, different imaging conditions. Typically, at least one of the images is a brightfield image that is acquired under violet lighting conditions (e.g., under lighting by light at a wavelength within the range of 400 nm-450 nm). Further typically, at least one of the images is a fluorescent image. A computer processor combines data from each of the plurality of images such as to generate an artificial color microscopic image of the microscopic imaging field that appears like a color smear image. For some applications, the computer processor runs a neural network such as to combine the images to generate an artificial color microscopic image of the microscopic imaging field that appears like a color smear image. Typically, one or more color models such as RGB, CIE, HSV, and/or a combination thereof is used to generate the artificial color microscopic image.
Typically, the image that was acquired under brightfield, violet lighting conditions is mapped to a red channel of the artificial color microscopic image. Further typically, the image is converted to a negative contrast image before being mapped to the red channel. For some applications, the result of mapping to the negative contrast image of the image acquired under brightfield, violet lighting conditions is that red blood cells have a similar appearance to the appearance of red blood cells in a color smear image (e.g., similar to those generated using Giemsa or Wright-Romanowsky smear staining).
For some applications, three images are acquired under respective imaging modalities. For example, in addition to the image acquired under brightfield violet lighting conditions, two fluorescent images may be acquired. For example, the two fluorescent images may be acquired after exciting the blood sample with light at respective wavelength bands (e.g., UV light, and blue light). Alternatively, the two fluorescent images may be acquired after exciting the sample with light at the same wavelength band, but using respective, different emission filters. Typically, the second image is mapped to a second color channel of the artificial color microscopic image, and the third image is mapped to a third color channel of the artificial color microscopic image. For example, when an RGB color model is used, the first image may be mapped to the red channel (as described above), the second image mapped to the green channel, and the third image mapped to the blue channel.
There is therefore provided, in accordance with some applications of the present invention, a method for use with a blood sample, the method including:
In some applications, the first one of the three images is an image acquired under off-focus, violet-light brightfield imaging conditions.
In some applications, generating the artificial color microscopic image of the microscopic imaging field includes using a neural network to generate the artificial color microscopic image of the microscopic imaging field.
In some applications, generating the artificial color microscopic image of the microscopic imaging field includes using a color model selected from the group consisting of: RGB, CIE, HSV, and a combination thereof.
In some applications, mapping the first one of the three images to the red channel of the artificial RGB microscopic image includes generating a negative contrast image of the first one of the three images and mapping the negative contrast image to the red channel of the artificial RGB microscopic image.
There is further provided, in accordance with some applications of the present invention, apparatus for use with a blood sample, the apparatus including:
In some applications, the microscope is configured to acquire the first one of the three images is an image acquired under off-focus, violet-light brightfield imaging conditions.
In some applications, the computer processor is configured to generate the artificial color microscopic image of the microscopic imaging field using a neural network.
In some applications, the computer processor is configured to generate the artificial color microscopic image of the microscopic imaging field using a color model selected from the group consisting of: RGB, CIE, HSV, and a combination thereof.
In some applications, the computer processor is configured to the first one of the three images to the red channel of the artificial RGB microscopic image by generating a negative contrast image of the first one of the three images and mapping the negative contrast image to the red channel of the artificial RGB microscopic image.
There is further provided, in accordance with some applications of the present invention, a method for use with a blood sample, the method including:
In some applications, combining data from each of the plurality of images such as to generate an artificial color microscopic image of the microscopic imaging field that appears like a color smear image includes using a neural network to combine data from each of the plurality of images such as to generate an artificial color microscopic image of the microscopic imaging field that appears like a color smear image.
In some applications, combining data from each of the plurality of images such as to generate an artificial color microscopic image of the microscopic imaging field that appears like a color smear image includes using a color model selected from the group consisting of: RGB, CIE, HSV, and a combination thereof.
There is further provided, in accordance with some applications of the present invention, apparatus for use with a blood sample, the apparatus including:
In some applications, the computer processor is configured to combine data from each of the plurality of images such as to generate an artificial color microscopic image of the microscopic imaging field that appears like a color smear image using a neural network.
In some applications, the computer processor is configured to combine data from each of the plurality of images such as to generate an artificial color microscopic image of the microscopic imaging field that appears like a color smear image using a color model selected from the group consisting of: RGB, CIE, HSV, and a combination thereof.
There is further provided, in accordance with some applications of the present invention, a method for use with a blood sample, the method including:
In some applications, generating the artificial color microscopic image of the microscopic imaging field includes using a neural network to generate the artificial color microscopic image of the microscopic imaging field.
In some applications, generating the artificial color microscopic image of the microscopic imaging field includes using a color model selected from the group consisting of: RGB, CIE, HSV, and a combination thereof.
In some applications, generating normalized versions of each of the images includes, for at least one of the images:
In some applications, generating normalized versions of each of the images further includes, for the at least one of the images:
There is further provided, in accordance with some applications of the present invention, apparatus for use with a blood sample, the apparatus including:
In some applications, the computer processor is configured to generate the artificial color microscopic image of the microscopic imaging field using a neural network.
In some applications, the computer processor is configured to generate the artificial color microscopic image of the microscopic imaging field using a color model selected from the group consisting of: RGB, CIE, HSV, and a combination thereof.
In some applications, the computer processor is configured to generate the normalized versions of each of the images by, for at least one of the images:
In some applications, the computer processor is configured to generate the normalized versions of each of the images by, for the at least one of the images:
There is further provided, in accordance with some applications of the present invention, a method for use with a blood sample, the method including:
In some applications, generating the artificial color microscopic image of the microscopic imaging field includes using a neural network to generate the artificial color microscopic image of the microscopic imaging field.
In some applications, generating the artificial color microscopic image of the microscopic imaging field includes using a color model selected from the group consisting of: RGB, CIE, HSV, and a combination thereof.
In some applications, generating the normalized version of the initial color image includes:
In some applications, generating the normalized version of the initial color image further includes:
There is further provided, in accordance with some applications of the present invention, apparatus for use with a blood sample, the apparatus including:
In some applications, the computer processor is configured to generate the artificial color microscopic image of the microscopic imaging field includes using a neural network.
In some applications, the computer processor is configured to generate the artificial color microscopic image of the microscopic imaging field includes using a color model selected from the group consisting of: RGB, CIE, HSV, and a combination thereof.
In some applications, the computer processor is configured to generate the normalized version of the initial color image by:
In some applications, the computer processor is configured to generate the normalized version of the initial color image by:
The present invention will be more fully understood from the following detailed description of embodiments thereof, taken together with the drawings, in which:
Reference is now made to
A computer processor 28 typically receives and processes optical measurements that are performed by the optical measurement device. Further typically, the computer processor controls the acquisition of optical measurements that arc performed by the one or more optical measurement devices. The computer processor communicates with a memory 30. A user (e.g., a laboratory technician, or an individual from whom the sample was drawn) sends instructions to the computer processor via a user interface 32. For some applications, the user interface includes a keyboard, a mouse, a joystick, a touchscreen device (such as a smartphone or a tablet computer), a touchpad, a trackball, a voice-command interface, and/or other types of user interfaces that are known in the art. Typically, the computer processor generates an output via an output device 34. Further typically, the output device includes a display, such as a monitor, and the output includes an output that is displayed on the display. For some applications, the processor generates an output on a different type of visual, text, graphics, tactile, audio, and/or video output device, e.g., speakers, headphones, a smartphone, or a tablet computer. For some applications, user interface 32 acts as both an input interface and an output interface, i.e., it acts as an input/output interface. For some applications, the processor generates an output on a computer-readable medium (e.g., a non-transitory computer-readable medium), such as a disk, or a portable USB drive, and/or generates an output on a printer.
Reference is now made to
Typically, the optical measurement unit includes microscope system 37 (shown in
Reference is now made to
Reference is made to
For some applications, a sample carrier as shown in
For some applications, one or more staining substances are used to stain the first portion of the blood sample (which is placed inside first set 52 of sample chambers) before the sample is imaged microscopically. For example, the staining substance may be configured to stain DNA with preference over staining of other cellular components. Alternatively, the staining substance may be configured to stain all cellular nucleic acids with preference over staining of other cellular components. For example, the sample may be stained with Acridine Orange reagent, Hoechst reagent, and/or any other staining substance that is configured to preferentially stain DNA and/or RNA within the blood sample. Optionally, the staining substance is configured to stain all cellular nucleic acids but the staining of DNA and RNA are each more prominently visible under some lighting and filter conditions, as is known, for example, for Acridine Orange. Images of the sample may be acquired using imaging conditions that allow detection of cells (e.g., brightfield) and/or imaging conditions that allow visualization of stained bodies (e.g. appropriate fluorescent illumination). Typically, the first portion of the sample is stained with Acridine Orange and with a Hoechst reagent. For example, the first (diluted) portion of the blood sample may be prepared using techniques as described in U.S. Pat. No. 9,329,129 to Pollak, which is incorporated herein by reference, and which describes a method for preparation of blood samples for analysis that involves a dilution step, the dilution step facilitating the identification and/or counting of components within microscopic images of the sample. For some applications, the first portion of the sample is stained with one or more stains that cause platelets within the sample to be visible under brightfield imaging conditions and/or under fluorescent imaging conditions, e.g., as described hereinabove. For example, the first portion of the sample may be stained with methylene blue and/or Romanowsky stains.
Referring again to
Typically, prior to being imaged microscopically, the first portion of blood (which is placed in first set 52 of sample chambers) is allowed to settle such as to form a monolayer of cells, e.g., using techniques as described in U.S. Pat. No. 9,329,129 to Pollak, which is incorporated herein by reference. For some applications, the first portion of blood is a cell suspension and the chambers belonging to the first set 52 of chambers each define a cavity 55 that includes a base surface 57 (shown in
It is noted that, in the context of the present application, the term monolayer is used to mean a layer of cells that have settled, such as to be disposed within a single focus level of the microscope. Within the monolayer there may be some overlap of cells, such that within certain areas there are two or more overlapping layers of cells. For example, red blood cells may overlap with each other within the monolayer, and/or platelets may overlap with, or be disposed above, red blood cells within the monolayer.
For some applications, the microscopic analysis of the first portion of the blood sample is performed with respect to the monolayer of cells. Typically, the first portion of the blood sample is imaged under brightfield imaging, i.e., under illumination from one or more light sources (e.g., one or more light emitting diodes, which typically emit light at respective spectral bands). Further typically, the first portion of the blood sample is additionally imaged under fluorescent imaging. Typically, the fluorescent imaging is performed by exciting stained objects (i.e., objects that have absorbed the stain(s)) within the sample by directing light toward the sample at known excitation wavelengths (i.e., wavelengths at which it is known that stained objects emit fluorescent light if excited with light at those wavelengths), and detecting the fluorescent light. Typically, for the fluorescent imaging, a separate set of light sources (e.g., one or more light emitting diodes) is used to illuminate the sample at the known excitation wavelengths.
As described with reference to US 2019/0302099 to Pollak, which is incorporated herein by reference, for some applications, sample chambers belonging to set 52 (which is used for microscopy measurements) have different heights from each other, in order to facilitate different measurands being measured using microscope images of respective sample chambers, and/or different sample chambers being used for microscopic analysis of respective sample types. For example, if a blood sample, and/or a monolayer formed by the sample, has a relatively low density of red blood cells, then measurements may be performed within a sample chamber of the sample carrier having a greater height (i.e., a sample chamber of the sample carrier having a greater height relative to a different sample chamber having a relatively lower height), such that there is a sufficient density of cells, and/or such that there is a sufficient density of cells within the monolayer formed by the sample, to provide statistically reliable data. Such measurements may include, for example red blood cell density measurements, measurements of other cellular attributes, (such as counts of abnormal red blood cells, red blood cells that include intracellular bodies (e.g., pathogens, Howell-Jolly bodies), etc.), and/or hemoglobin concentration. Conversely, if a blood sample, and/or a monolayer formed by the sample, has a relatively high density of red blood cells, then such measurements may be performed upon a sample chamber of the sample carrier having a relatively low height, for example, such that there is a sufficient sparsity of cells, and/or such that there is a sufficient sparsity of cells within the monolayer of cells formed by the sample, that the cells can be identified within microscopic images. For some applications, such methods are performed even without the variation in height between the sample chambers belonging to set 52 being precisely known.
For some applications, based upon the measurand that is being measured, the sample chamber within the sample carrier upon which to perform optical measurements is selected. For example, a sample chamber of the sample carrier having a greater height may be used to perform a white blood cell count (e.g., to reduce statistical errors which may result from a low count in a shallower region), white blood cell differentiation, and/or to detect more rare forms of white blood cells. Conversely, in order to determine mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), red blood cell distribution width (RDW), red blood cell morphologic features, and/or red blood cell abnormalities, microscopic images may be obtained from a sample chamber of the sample carrier having a relatively low height, since in such sample chambers the cells arc relatively sparsely distributed across the area of the region, and/or form a monolayer in which the cells are relatively sparsely distributed. Similarly, in order to count platelets, classify platelets, and/or extract any other attributes (such as volume) of platelets, microscopic images may be obtained from a sample chamber of the sample carrier having a relatively low height, since within such sample chambers there are fewer red blood cells which overlap (fully or partially) with the platelets in microscopic images, and/or in a monolayer.
In accordance with the above-described examples, it is preferable to use a sample chamber of the sample carrier having a lower height for performing optical measurements for measuring some measurands within a sample (such as a blood sample), whereas it is preferable to use a sample chamber of the sample carrier having a greater height for performing optical measurements for measuring other measurands within such a sample. Therefore, for some applications, a first measurand within a sample is measured, by performing a first optical measurement upon (e.g., by acquiring microscopic images of) a portion of the sample that is disposed within a first sample chamber belonging to set 52 of the sample carrier, and a second measurand of the same sample is measured, by performing a second optical measurement upon (e.g., by acquiring microscopic images of) a portion of the sample that is disposed within a second sample chamber of set 52 of the sample carrier. For some applications, the first and second measurands are normalized with respect to each other, for example, using techniques as described in US 2019/0145963 to Zait, which is incorporated herein by reference.
Typically, in order to perform optical density measurements upon the sample, it is desirable to know the optical path length, the volume, and/or the thickness of the portion of the sample upon which the optical measurements were performed, as precisely as possible. Typically, an optical density measurement is performed on the second portion of the sample (which is typically placed into second set 54 of sample chambers in an undiluted form). For example, the concentration and/or density of a component may be measured by performing optical absorption, transmittance, fluorescence, and/or luminescence measurements upon the sample.
Referring again to
As described hereinabove, while the sample is disposed in the sample carrier, optical measurements are performed upon the sample using one or more optical measurement devices 24. Typically, the sample is viewed by the optical measurement devices via the glass layer, glass being transparent at least to wavelengths that are typically used by the optical measurement device. Typically, the sample carrier is inserted into optical measurement unit 31, which houses the optical measurement device while the optical measurements are performed. Typically, the optical measurement unit houses the sample carrier such that the molded layer is disposed above the glass layer, and such that the optical measurement unit is disposed below the glass layer of the sample carrier and is able to perform optical measurements upon the sample via the glass layer. The sample carrier is formed by adhering the glass layer to the molded component. For example, the glass layer and the molded component may be bonded to each other during manufacture or assembly (e.g. using thermal bonding, solvent-assisted bonding, ultrasonic welding, laser welding, heat staking, adhesive, mechanical clamping and/or additional substrates). For some applications, the glass layer and the molded component are bonded to each other during manufacture or assembly using adhesive layer 46.
For some microscopy applications, microscopic images of imaging fields are acquired using a plurality of different imaging modalities. For example, as described hereinabove, brightfield images may be acquired under illumination of the sample at several, respective, different wavelength bands. The brightfield images may be acquired while cells (e.g., a monolayer of the cells) are in focus or out of focus. Alternatively or additionally, fluorescent images are acquired by exciting stained objects (i.e., objects that have absorbed the stain(s)) within the sample by directing light toward the sample at known excitation wavelengths (i.e., wavelengths at which it is known that stained objects emit fluorescent light if excited with light at those wavelengths), and detecting the fluorescent light. Respective fluorescent images are acquired by exciting the sample with light at respective, different wavelength bands, or by exciting the sample with light a given wavelength band and then using emission filters that filter light that is emitted from the sample at respective wavelength bands.
Typically, the computer processor analyzes the microscopic images and/or other data relating to the sample (e.g., optical absorption measurements), in order to determine properties of the sample. For some applications, the computer processor additionally outputs images of the sample to a user via output device 34. It may be challenging though for a human observer to extract useful information from the images, especially if that information is contained in the overlap between images that were acquired using respective, different imaging modalities and these images arc overlaid upon each other as black-and-white or grayscale images. For example, in order to verify that an element is an intraerythrocytic parasite, it may be helpful to see a single image in which the parasite candidate is visible and red blood cells are visible. The red blood cells are typically visible in brightfield images (e.g., brightfield images acquired under violet illumination), whereas the parasites are typically visible in fluorescent images. Therefore, it is helpful to see such images overlaid upon each other, but in which elements from the respective imaging modalities are visible without interfering with each other. Similarly, in order to see morphological features of white blood cells (which can help in the classification of an element as a white blood cell, and/or as a given type of white blood cell), it is typically helpful to see respective fluorescent images acquired under respective fluorescent illumination conditions overlaid upon each other.
Therefore, in accordance with some applications of the present invention, a plurality of images of a microscopic imaging field of a blood sample are acquired, each of the images being acquired using respective, different imaging conditions. Typically, at least one of the images is a brightfield image that is acquired under violet lighting conditions (e.g., under lighting by light at a wavelength within the range of 400 nm-450 nm). For some applications, the brightfield image is an off-focus image that is acquired under violet lighting conditions. Further typically, at least one of the images is a fluorescent image. A computer processor combines data from each of the plurality of images such as to generate an artificial color microscopic image of the microscopic imaging field that appears like a color smear image. Typically, one or more color models such as RGB, CIE, HSV, and/or a combination thereof is used to generate the artificial color microscopic image.
Typically, the image that was acquired under brightfield, violet lighting conditions is mapped to a red channel of the artificial color microscopic image. Further typically, the image is converted to a negative contrast image before being mapped to the red channel. For some applications, the result of mapping to the negative contrast image of the image acquired under brightfield, violet lighting conditions is that red blood cells have a similar appearance to the appearance of red blood cells in a color smear image (e.g., similar to those generated using Giemsa or Wright-Romanowsky smear staining). Typically, the brightfield image that was acquired under violet lighting conditions is used in the aforementioned manner, since violet light is absorbed strongly by hemoglobin and therefore red blood cells appear as red once the contrast of the image is made negative and the image is mapped to the red channel.
For some applications, three images are acquired under respective imaging modalities. For example, in addition to the image acquired under brightfield violet lighting conditions, two fluorescent images may be acquired. For example, the two fluorescent images may be acquired after exciting the blood sample with light at respective wavelength bands. Alternatively, the two fluorescent images may be acquired after exciting the sample with light at the same wavelength band, but using respective, different emission filters. Typically, the second image is mapped to a second color channel of the artificial color microscopic image, and the third image is mapped to a third color channel of the artificial color microscopic image. For example, when an RGB color model is used, the first image may be mapped to the red channel (as described above), the second image mapped to the green channel, and the third image mapped to the blue channel. For some applications, one of the second and third images is acquired while the sample is excited using light (e.g., UV light) that causes cell nuclei (e.g., DNA of the cell nuclei) to fluoresce. Alternatively or additionally, a second one of the second and third images is acquired while the sample is excited using light (e.g., blue light) that causes RNA and/or cytoplasm to fluoresce. For some applications, imaging modalities are used that are similar to those used in images generated using Giemsa or Wright-Romanowsky smear staining.
For some applications, each of the fluorescent images is acquired using a relatively long exposure time. For example, this may be used in order to visualize reticulocytes as well as platelets. Alternatively, one of the fluorescent images may be acquired using a relatively short exposure time, and the other one of the fluorescent images may be acquired using a relatively short exposure time. The long and short exposure fluorescent images typically contain different information. The images acquired using the short exposure are typically optimized to provide data relating to white blood cells and other high intensity objects, while the images acquired using the long exposure time are typically optimized to provide data relating to low intensity objects such as reticulocytes, platelets, parasites, ghost cells, etc.
For some applications, the short-exposure-time images are combined with the long-exposure-time images into a single fluorescent image (for example, by replacing over-exposed regions in the long-exposure-image image with the corresponding region in the short-exposure-time image). For some applications, the resultant composite image (and/or a composite image that is generated using a different composite-image-generation technique) is mapped to one of the channels of an artificial color images, e.g., using the techniques described hereinabove.
For some applications, a neural network is used in the generation of an artificial color image. In some cases, an artificial color image generated using the methods described hereinabove may have different characteristics from the type of images that are commonly used in the field. For example, such images may differ from standard images in color, intensity resolution, shading, etc. For some applications, a convolutional neural network is used to generate an image that is more similar to standard images in the field, such that the image has a similar appearance to that of a color smear image (e.g., similar to an image generated using Giemsa or Wright-Romanow sky smear staining).
For some applications, one or more of the images that are mapped to the color image is normalized. For example, the image may be normalized by dividing the image by a background map. Alternatively or additionally, a function of the image (such as optical density) may be used in the color image. For some applications, the displayed color image is normalized such that that relevant features arc of similar magnitude in all of the channels. For some applications, one or more of the original images, and/or the displayed color image is normalized by determining a maximum intensity within the image, and removing all pixels having an intensity that is less than a given proportion of the maximum intensity (e.g., less than half of the maximum intensity), and renormalizing the pixel intensity as described below. For some applications, one or more of the original images, and/or the displayed color image is normalized in the following manner. An intensity histogram of the image is generated. For each pixel within the image that has an intensity that is at least equal to half of the maximum intensity, a closest local maximum in the intensity histogram having an intensity that is greater than half of the maximum intensity within the image is identified. The intensity of the pixel is then normalized based upon the difference between the maximum intensity and the intensity of the local maximum. For example, a given pixel may be assigned an intensity based upon the following formula:
INp=N*(Ip−Vmin)/(Vmin−Vmax), for Vmin<=Ip<=Vmax;
INp=N for Ip>Vmax;
INp=0 for Ip<Vmin
where:
Reference is now made to
Referring to
Referring to
Referring to
Referring to
For some applications, the apparatus and methods described herein are applied to a biological sample, such as, blood, saliva, semen, sweat, sputum, vaginal fluid, stool, breast milk, bronchoalveolar lavage, gastric lavage, tears and/or nasal discharge, mutatis mutandis. The biological sample may be from any living creature, and is typically from warm blooded animals. For some applications, the biological sample is a sample from a mammal, e.g., from a human body. For some applications, the sample is taken from any domestic animal, zoo animals and farm animals, including but not limited to dogs, cats, horses, cows and sheep. Alternatively or additionally, the biological sample is taken from animals that act as disease vectors including deer or rats.
For some applications, the apparatus and methods described herein are applied to a non-bodily sample. For some applications, the sample is an environmental sample, such as, a water (e.g. groundwater) sample, surface swab, soil sample, air sample, or any combination thereof, mutatis mutandis. In some embodiments, the sample is a food sample, such as, a meat sample, dairy sample, water sample, wash-liquid sample, beverage sample, and/or any combination thereof.
For some applications, the sample as described herein is a sample that includes blood or components thereof (e.g., a diluted or non-diluted whole blood sample, a sample including predominantly red blood cells, or a diluted sample including predominantly red blood cells), and parameters are determined relating to components in the blood such as platelets, white blood cells, anomalous white blood cells, circulating tumor cells, red blood cells, reticulocytes, Howell-Jolly bodies, etc.
Applications of the invention described herein can take the form of a computer program product accessible from a computer-usable or computer-readable medium (e.g., a non-transitory computer-readable medium) providing program code for use by or in connection with a computer or any instruction execution system, such as computer processor 28. For the purposes of this description, a computer-usable or computer readable medium can be any apparatus that can comprise, store, communicate, propagate, or transport the program for use by or in connection with the instruction execution system, apparatus, or device. The medium can be an electronic, magnetic, optical, electromagnetic, infrared, or semiconductor system (or apparatus or device) or a propagation medium. Typically, the computer-usable or computer readable medium is a non-transitory computer-usable or computer readable medium.
Examples of a computer-readable medium include a semiconductor or solid state memory, magnetic tape, a removable computer diskette, a random-access memory (RAM), a read-only memory (ROM), a rigid magnetic disk and an optical disk. Current examples of optical disks include compact disk-read only memory (CD-ROM), compact disk-read/write (CD-R/W) and DVD.
A data processing system suitable for storing and/or executing program code will include at least one processor (e.g., computer processor 28) coupled directly or indirectly to memory elements (e.g., memory 30) through a system bus. The memory elements can include local memory employed during actual execution of the program code, bulk storage, and cache memories which provide temporary storage of at least some program code in order to reduce the number of times code must be retrieved from bulk storage during execution. The system can read the inventive instructions on the program storage devices and follow these instructions to execute the methodology of the embodiments of the invention.
Network adapters may be coupled to the processor to enable the processor to become coupled to other processors or remote printers or storage devices through intervening private or public networks. Modems, cable modem and Ethernet cards are just a few of the currently available types of network adapters.
Computer program code for carrying out operations of the present invention may be written in any combination of one or more programming languages, including an object-oriented programming language such as Java, Smalltalk, C++ or the like and conventional procedural programming languages, such as the C programming language or similar programming languages.
It will be understood that algorithms described herein, can be implemented by computer program instructions. These computer program instructions may be provided to a processor of a general-purpose computer, special purpose computer, or other programmable data processing apparatus to produce a machine, such that the instructions, which execute via the processor of the computer (e.g., computer processor 28) or other programmable data processing apparatus, create means for implementing the functions/acts specified in the algorithms described in the present application. These computer program instructions may also be stored in a computer-readable medium (e.g., a non-transitory computer-readable medium) that can direct a computer or other programmable data processing apparatus to function in a particular manner, such that the instructions stored in the computer-readable medium produce an article of manufacture including instruction means which implement the function/act specified in the flowchart blocks and algorithms. The computer program instructions may also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce a computer implemented process such that the instructions which execute on the computer or other programmable apparatus provide processes for implementing the functions/acts specified in the algorithms described in the present application.
Computer processor 28 is typically a hardware device programmed with computer program instructions to produce a special purpose computer. For example, when programmed to perform the algorithms described herein, computer processor 28 typically acts as a special purpose artificial-image-generation computer processor. Typically, the operations described herein that are performed by computer processor 28 transform the physical state of memory 30, which is a real physical article, to have a different magnetic polarity, electrical charge, or the like depending on the technology of the memory that is used.
The apparatus and methods described herein may be used in conjunction with apparatus and methods described in any one of the following patents or patent applications, all of which are incorporated herein by reference:
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.
The present application is a US national phase application of PCT Application No. PCT/IB2020/061736 to Halperin (published as WO 21/116962), which claims priority from U.S. Provisional Patent Application No. 62/946,988 to Halperin et al., filed Dec. 12, 2019, entitled “Artificial generation of a color blood smear image,” which is incorporated herein by reference. . .
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/IB2020/061736 | 12/10/2020 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2021/116962 | 6/17/2021 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
3203768 | Tiller et al. | Aug 1965 | A |
3603156 | Konkol | Sep 1971 | A |
3676076 | Grady | Jul 1972 | A |
3786184 | Pieters | Jan 1974 | A |
3916205 | Kleinerman | Oct 1975 | A |
3967056 | Yata et al. | Jun 1976 | A |
4030888 | Yamamoto | Jun 1977 | A |
4076419 | Kleker | Feb 1978 | A |
4097845 | Bacus | Jun 1978 | A |
4199748 | Bacus | Apr 1980 | A |
4209548 | Bacus | Sep 1980 | A |
4350884 | Vollath | Sep 1982 | A |
4453266 | Bacus | Jun 1984 | A |
4454235 | Johnson | Jun 1984 | A |
4494479 | Drury et al. | Jan 1985 | A |
4580895 | Patel | Apr 1986 | A |
4700298 | Palcic et al. | Oct 1987 | A |
4761381 | Blatt et al. | Aug 1988 | A |
4774192 | Terminiello et al. | Sep 1988 | A |
4803352 | Bierleutgeb | Feb 1989 | A |
4849430 | Fleet | Jul 1989 | A |
4851330 | Kohne | Jul 1989 | A |
4902101 | Fujihara et al. | Feb 1990 | A |
5001067 | Coleman et al. | Mar 1991 | A |
5064282 | Curtis | Nov 1991 | A |
5229265 | Tometsko | Jul 1993 | A |
5300779 | Hillman et al. | Apr 1994 | A |
5331958 | Oppenheimer | Jul 1994 | A |
5430542 | Shepherd et al. | Jul 1995 | A |
5470751 | Sakata et al. | Nov 1995 | A |
5499097 | Ortyn et al. | Mar 1996 | A |
5566249 | Rosenlof et al. | Oct 1996 | A |
5625706 | Lee et al. | Apr 1997 | A |
5663057 | Drocourt et al. | Sep 1997 | A |
5671288 | Wilhelm et al. | Sep 1997 | A |
5672861 | Fairley et al. | Sep 1997 | A |
5674457 | Williamsson et al. | Oct 1997 | A |
5745804 | Iwane | Apr 1998 | A |
5782770 | Mooradian et al. | Jul 1998 | A |
5827190 | Palcic et al. | Oct 1998 | A |
5834217 | Levine et al. | Nov 1998 | A |
5932872 | Price | Aug 1999 | A |
5948686 | Wardlaw et al. | Sep 1999 | A |
5978497 | Lee et al. | Nov 1999 | A |
5985595 | Krider et al. | Nov 1999 | A |
5993702 | Davis | Nov 1999 | A |
6005964 | Reid et al. | Dec 1999 | A |
6007996 | McNamara et al. | Dec 1999 | A |
6027695 | Oldenburg | Feb 2000 | A |
6064474 | Lee | May 2000 | A |
6074879 | Zelmanovic | Jun 2000 | A |
6101404 | Yoon | Aug 2000 | A |
6235536 | Wardlaw | May 2001 | B1 |
6262423 | Hell et al. | Jul 2001 | B1 |
6262798 | Shepherd et al. | Jul 2001 | B1 |
6320979 | Melen | Nov 2001 | B1 |
6330348 | Kerschmann et al. | Dec 2001 | B1 |
6339472 | Hafeman | Jan 2002 | B1 |
6350613 | Wardlaw et al. | Feb 2002 | B1 |
6448024 | Bruegger | Sep 2002 | B1 |
6519355 | Nelson | Feb 2003 | B2 |
6554788 | Hunley et al. | Apr 2003 | B1 |
6582964 | Samsoondar et al. | Jun 2003 | B1 |
6611777 | Samsoondar | Aug 2003 | B2 |
6632681 | Chu | Oct 2003 | B1 |
6658143 | Hansen | Dec 2003 | B2 |
6664528 | Cartlidge et al. | Dec 2003 | B1 |
6711516 | Samsoondar | Mar 2004 | B2 |
6799119 | Voorhees et al. | Sep 2004 | B1 |
6819408 | Scrivens et al. | Nov 2004 | B1 |
6831733 | Pettersson | Dec 2004 | B2 |
6834237 | Noergaard et al. | Dec 2004 | B2 |
6836559 | Abdel-fattah | Dec 2004 | B2 |
6842233 | Narisada | Jan 2005 | B2 |
6866823 | Wardlaw | Mar 2005 | B2 |
6872930 | Cartlidge et al. | Mar 2005 | B2 |
6898451 | Wuori | May 2005 | B2 |
6903323 | Cartlidge et al. | Jun 2005 | B2 |
6929953 | Wardlaw et al. | Aug 2005 | B1 |
6949384 | Samsoondar | Sep 2005 | B2 |
6955872 | Maples et al. | Oct 2005 | B2 |
6956650 | Boas | Oct 2005 | B2 |
6989891 | Braig et al. | Jan 2006 | B2 |
7027628 | Gagnon | Apr 2006 | B1 |
7030351 | Wasserman | Apr 2006 | B2 |
7034883 | Rosenqvist | Apr 2006 | B1 |
7105795 | Cartlidge et al. | Sep 2006 | B2 |
7132636 | Cartlidge | Nov 2006 | B1 |
7133547 | Marcelpoil | Nov 2006 | B2 |
7151246 | Fein et al. | Dec 2006 | B2 |
7155049 | Wetzel | Dec 2006 | B2 |
7248716 | Fein et al. | Jul 2007 | B2 |
7274810 | Reeves et al. | Sep 2007 | B2 |
7283217 | Ikeuchi | Oct 2007 | B2 |
7288751 | Cartlidge et al. | Oct 2007 | B2 |
7305109 | Gagnon | Dec 2007 | B1 |
7324694 | Chapoulaud | Jan 2008 | B2 |
7329537 | Qiu | Feb 2008 | B2 |
7338168 | Cartlidge et al. | Mar 2008 | B2 |
7344890 | Perez et al. | Mar 2008 | B2 |
7346205 | Walker, Jr. | Mar 2008 | B2 |
7369696 | Arini et al. | May 2008 | B2 |
7387898 | Gordon | Jun 2008 | B1 |
7411680 | Chang | Aug 2008 | B2 |
7417213 | Krief et al. | Aug 2008 | B2 |
7385168 | Cartlidge et al. | Sep 2008 | B2 |
7425421 | Dertinger | Sep 2008 | B2 |
7439478 | Cartlidge et al. | Oct 2008 | B2 |
7450223 | Ikeuchi | Nov 2008 | B2 |
7450762 | Morell | Nov 2008 | B2 |
7460222 | Kalveram | Dec 2008 | B2 |
7490085 | Walker et al. | Feb 2009 | B2 |
7493219 | Qi | Feb 2009 | B1 |
7580120 | Hamada | Aug 2009 | B2 |
7599893 | Sapir | Oct 2009 | B2 |
7601938 | Cartlidge et al. | Oct 2009 | B2 |
7602954 | Marcelpoil | Oct 2009 | B2 |
7605356 | Krief | Oct 2009 | B2 |
7609369 | Simon-Lopez | Oct 2009 | B2 |
7630063 | Padmanabhan | Dec 2009 | B2 |
7633604 | Ikeuchi | Dec 2009 | B2 |
7638748 | Krief et al. | Dec 2009 | B2 |
7663738 | Johansson | Feb 2010 | B2 |
7668362 | Olson | Feb 2010 | B2 |
7692131 | Fein et al. | Apr 2010 | B2 |
7697764 | Kataoka | Apr 2010 | B2 |
7702181 | Gouch | Apr 2010 | B2 |
7706862 | Alfano et al. | Apr 2010 | B2 |
7713474 | Schulman et al. | May 2010 | B2 |
7747153 | Ibaraki | Jun 2010 | B2 |
7765069 | Ostoich | Jul 2010 | B2 |
7777869 | Nerin | Aug 2010 | B2 |
7787109 | Dosmann et al. | Aug 2010 | B2 |
7796797 | Nakaya et al. | Sep 2010 | B2 |
7863552 | Cartlidge et al. | Jan 2011 | B2 |
7869009 | Dosmann et al. | Jan 2011 | B2 |
7894047 | Hamada | Feb 2011 | B2 |
7911617 | Padmanabhan | Mar 2011 | B2 |
7925070 | Sumida | Apr 2011 | B2 |
7929121 | Wardlaw | Apr 2011 | B2 |
7933435 | Hunter | Apr 2011 | B2 |
7936913 | Nordell | May 2011 | B2 |
7951599 | Levine | May 2011 | B2 |
7995200 | Matsumoto | Aug 2011 | B2 |
7998435 | Reed | Aug 2011 | B2 |
8000511 | Perz | Aug 2011 | B2 |
8044974 | Sumida | Oct 2011 | B2 |
8045782 | Li | Oct 2011 | B2 |
8055471 | Qi | Nov 2011 | B2 |
8064680 | Ramoser | Nov 2011 | B2 |
8077296 | Wardlaw | Dec 2011 | B2 |
8081303 | Levine | Dec 2011 | B2 |
8105554 | Kanigan et al. | Jan 2012 | B2 |
8125643 | Hansen | Feb 2012 | B2 |
D655421 | Lee et al. | Mar 2012 | S |
8131035 | Grady | Mar 2012 | B2 |
8131052 | Alexandrov | Mar 2012 | B2 |
8150114 | Svanberg | Apr 2012 | B2 |
8154713 | Simon-Lopez | Apr 2012 | B2 |
8165385 | Reeves | Apr 2012 | B2 |
8175353 | Westphal | May 2012 | B2 |
8179597 | Namba | May 2012 | B2 |
8184273 | Dosmann | May 2012 | B2 |
8192995 | Zhang et al. | Jun 2012 | B2 |
8216832 | Battrell et al. | Jul 2012 | B2 |
8224058 | Lindberg | Jul 2012 | B2 |
8269954 | Levine | Sep 2012 | B2 |
8280134 | Hoyt | Oct 2012 | B2 |
8310659 | Wardlaw | Nov 2012 | B2 |
8320655 | Sarachan | Nov 2012 | B2 |
8327724 | Fairs | Dec 2012 | B2 |
8331642 | Zerfass | Dec 2012 | B2 |
8339586 | Zahniser | Dec 2012 | B2 |
8345227 | Zahniser | Jan 2013 | B2 |
8351676 | Dai | Jan 2013 | B2 |
8363221 | Hansen | Jan 2013 | B2 |
8379944 | Grady | Feb 2013 | B2 |
8406498 | Ortyn | Mar 2013 | B2 |
8428331 | Dimarzio | Apr 2013 | B2 |
8432392 | Kim | Apr 2013 | B2 |
8477294 | Zahniser | Jul 2013 | B2 |
8481303 | Faris et al. | Jul 2013 | B2 |
8488111 | Zahniser | Jul 2013 | B2 |
8491499 | Choi et al. | Jul 2013 | B2 |
8526704 | Dobbe | Sep 2013 | B2 |
8570496 | Chen | Oct 2013 | B2 |
8582924 | De La Torre-bueno | Nov 2013 | B2 |
8638427 | Wardlaw | Jan 2014 | B2 |
8712142 | Rajpoot | Apr 2014 | B2 |
8736824 | Matsui | May 2014 | B2 |
8744165 | Liu | Jun 2014 | B2 |
8778687 | Levine | Jul 2014 | B2 |
8787650 | Marugame | Jul 2014 | B2 |
8792693 | Satish | Jul 2014 | B2 |
8837803 | Wang et al. | Sep 2014 | B2 |
8849024 | Shinoda | Sep 2014 | B2 |
8873827 | Mcculloch | Oct 2014 | B2 |
8877458 | Maurer | Nov 2014 | B2 |
8878923 | Henderson | Nov 2014 | B2 |
8885154 | Wardlaw | Nov 2014 | B2 |
8885912 | Sui | Nov 2014 | B2 |
8891851 | Spaulding | Nov 2014 | B2 |
8922761 | Zahniser | Dec 2014 | B2 |
8942458 | Takahashi | Jan 2015 | B2 |
8964171 | Zahniser | Feb 2015 | B2 |
8992750 | Beaty | Mar 2015 | B1 |
8994930 | Levine | Mar 2015 | B2 |
9012868 | Courtney et al. | Apr 2015 | B2 |
9041792 | Van Leeuwen | May 2015 | B2 |
9050595 | Miller et al. | Jun 2015 | B2 |
9064301 | Zie et al. | Jun 2015 | B2 |
9046473 | Levine | Sep 2015 | B2 |
9176121 | Winkelman et al. | Nov 2015 | B2 |
9186843 | Chan et al. | Nov 2015 | B2 |
9240043 | Christiansen | Jan 2016 | B2 |
9322767 | Ehrenkranz | Apr 2016 | B2 |
9329129 | Pollak et al. | May 2016 | B2 |
9342734 | Lin et al. | May 2016 | B2 |
9404852 | Braig et al. | Aug 2016 | B2 |
9470609 | Wimberger-friedl | Oct 2016 | B2 |
9477875 | Ohya | Oct 2016 | B2 |
9522396 | Bachelet | Dec 2016 | B2 |
9528978 | Yamada | Dec 2016 | B2 |
9588033 | Zahniser et al. | Mar 2017 | B2 |
9767343 | Jones et al. | Sep 2017 | B1 |
9820990 | Pak et al. | Nov 2017 | B2 |
9933363 | Danuser et al. | Apr 2018 | B2 |
9934571 | Ozaki | Apr 2018 | B2 |
9976945 | Kendall et al. | May 2018 | B2 |
10024858 | Smith et al. | Jul 2018 | B2 |
10061972 | Champlin | Aug 2018 | B2 |
10093957 | Pollak et al. | Oct 2018 | B2 |
10169861 | Ozaki et al. | Jan 2019 | B2 |
10176565 | Greenfield | Jan 2019 | B2 |
10281386 | Hsu et al. | May 2019 | B2 |
10395368 | Berezhna | Aug 2019 | B2 |
10482595 | Yorav-Raphael | Nov 2019 | B2 |
10488644 | Eshel | Nov 2019 | B2 |
10508983 | Kendall et al. | Dec 2019 | B2 |
10527635 | Bhatia | Jan 2020 | B1 |
10640807 | Pollak | May 2020 | B2 |
10663712 | Eshel | May 2020 | B2 |
10843190 | Bachelet | Nov 2020 | B2 |
11099175 | Zait et al. | Aug 2021 | B2 |
11199690 | Eshel | Dec 2021 | B2 |
11609413 | Yorav-Raphael et al. | Mar 2023 | B2 |
20020009711 | Wada et al. | Jan 2002 | A1 |
20020028158 | Wardlaw et al. | Mar 2002 | A1 |
20020028471 | Oberhardt | Mar 2002 | A1 |
20030017085 | Kercso et al. | Mar 2003 | A1 |
20030161514 | Curry | Aug 2003 | A1 |
20030170613 | Straus | Sep 2003 | A1 |
20030197925 | Hamborg | Oct 2003 | A1 |
20030208140 | Pugh | Nov 2003 | A1 |
20030224522 | de Jong | Dec 2003 | A1 |
20030227612 | Fein et al. | Dec 2003 | A1 |
20030227673 | Nakagawa | Dec 2003 | A1 |
20030231791 | Torre-Bueno et al. | Dec 2003 | A1 |
20040240050 | Ogihara | Feb 2004 | A1 |
20040241677 | Lin et al. | Feb 2004 | A1 |
20040054283 | Corey et al. | Mar 2004 | A1 |
20040122216 | Nielsen | Jun 2004 | A1 |
20040132171 | Rule et al. | Jul 2004 | A1 |
20040170312 | Soenksen | Sep 2004 | A1 |
20040185447 | Maples et al. | Sep 2004 | A1 |
20040218804 | Affleck et al. | Nov 2004 | A1 |
20050089208 | Dong et al. | Apr 2005 | A1 |
20050109959 | Wasserman et al. | May 2005 | A1 |
20050175992 | Aberl et al. | Aug 2005 | A1 |
20050286800 | Gouch | Dec 2005 | A1 |
20060002817 | Bohm | Jan 2006 | A1 |
20060003458 | Golovchenko et al. | Jan 2006 | A1 |
20060045505 | Zeineh | Mar 2006 | A1 |
20060051778 | Kallick | Mar 2006 | A1 |
20060063185 | Vannier | Mar 2006 | A1 |
20060079144 | Klisch et al. | Apr 2006 | A1 |
20060187442 | Chang et al. | Aug 2006 | A1 |
20060190226 | Jojic et al. | Aug 2006 | A1 |
20060222567 | Kloepfer et al. | Oct 2006 | A1 |
20060223052 | MacDonald et al. | Oct 2006 | A1 |
20060223165 | Chang et al. | Oct 2006 | A1 |
20070252984 | Van Beek et al. | Jan 2007 | A1 |
20070054350 | Walker, Jr. | Mar 2007 | A1 |
20070076190 | Nakaya et al. | Apr 2007 | A1 |
20070161075 | Gleich | Jul 2007 | A1 |
20070172956 | Magari et al. | Jul 2007 | A1 |
20070231914 | Deng et al. | Oct 2007 | A1 |
20070243117 | Wardlaw et al. | Oct 2007 | A1 |
20070250301 | Vaisberg et al. | Oct 2007 | A1 |
20080019584 | Lindberg et al. | Jan 2008 | A1 |
20080020128 | van Ryper | Jan 2008 | A1 |
20080059135 | Murugkar et al. | Mar 2008 | A1 |
20080118399 | Fleming | May 2008 | A1 |
20080187466 | Wardlaw et al. | Aug 2008 | A1 |
20080212069 | Goldberg et al. | Sep 2008 | A1 |
20080260369 | Ibaraki | Oct 2008 | A1 |
20080273776 | Krief et al. | Nov 2008 | A1 |
20080305514 | Alford et al. | Dec 2008 | A1 |
20090066934 | Gao et al. | Mar 2009 | A1 |
20090074282 | Pinard et al. | Mar 2009 | A1 |
20090075324 | Pettersson | Mar 2009 | A1 |
20090086314 | Namba | Apr 2009 | A1 |
20090088336 | Burd et al. | Apr 2009 | A1 |
20090128618 | Fahn et al. | May 2009 | A1 |
20090185734 | Lindberg et al. | Jul 2009 | A1 |
20090191098 | Beard et al. | Jul 2009 | A1 |
20090195688 | Henderson et al. | Aug 2009 | A1 |
20090213214 | Yamada | Aug 2009 | A1 |
20090258347 | Scott | Oct 2009 | A1 |
20090269799 | Winkelman et al. | Oct 2009 | A1 |
20090291854 | Wiesinger-Mayr et al. | Nov 2009 | A1 |
20100003265 | Scheffler | Jan 2010 | A1 |
20100068747 | Herrenknecht | Mar 2010 | A1 |
20100104169 | Yamada | Apr 2010 | A1 |
20100112631 | Hur et al. | May 2010 | A1 |
20100120129 | Amshey et al. | May 2010 | A1 |
20100136556 | Friedberger et al. | Jun 2010 | A1 |
20100136570 | Goldberg et al. | Jun 2010 | A1 |
20100152054 | Love | Jun 2010 | A1 |
20100157086 | Segale et al. | Jun 2010 | A1 |
20100172020 | Price | Jul 2010 | A1 |
20100192706 | Fairs | Aug 2010 | A1 |
20100232675 | Ortyn et al. | Sep 2010 | A1 |
20100234703 | Sterling et al. | Sep 2010 | A1 |
20100253907 | Korb | Oct 2010 | A1 |
20100254596 | Xiong | Oct 2010 | A1 |
20100256918 | Chen et al. | Oct 2010 | A1 |
20100265323 | Perz | Oct 2010 | A1 |
20100272334 | Yamada et al. | Oct 2010 | A1 |
20100295998 | Sakai et al. | Nov 2010 | A1 |
20100300563 | Ramunas et al. | Dec 2010 | A1 |
20110007178 | Kahlman | Jan 2011 | A1 |
20110009163 | Fletcher | Jan 2011 | A1 |
20110030458 | Park et al. | Feb 2011 | A1 |
20110059481 | Wardlaw et al. | Mar 2011 | A1 |
20110102571 | Yoneyama | May 2011 | A1 |
20110123398 | Carrhilo et al. | May 2011 | A1 |
20110144480 | Lu et al. | Jun 2011 | A1 |
20110149097 | Danuser et al. | Jun 2011 | A1 |
20110151502 | Kendall et al. | Jun 2011 | A1 |
20110178716 | Krockenberger et al. | Jul 2011 | A1 |
20110212486 | Yamada | Sep 2011 | A1 |
20110243794 | Wardlaw | Oct 2011 | A1 |
20110249910 | Henderson | Oct 2011 | A1 |
20110275111 | Pettigrew et al. | Nov 2011 | A1 |
20110301012 | Dolecek et al. | Dec 2011 | A1 |
20120002195 | Wu et al. | Jan 2012 | A1 |
20120021951 | Hess et al. | Jan 2012 | A1 |
20120030618 | Leong et al. | Feb 2012 | A1 |
20120044342 | Hing et al. | Feb 2012 | A1 |
20120058504 | Li et al. | Mar 2012 | A1 |
20120092477 | Kawano et al. | Apr 2012 | A1 |
20120120221 | Dong et al. | May 2012 | A1 |
20120169863 | Bachelet et al. | Jul 2012 | A1 |
20120225446 | Wimberger-friedl et al. | Sep 2012 | A1 |
20120237107 | Tawfik et al. | Sep 2012 | A1 |
20120275671 | Eichhorn et al. | Nov 2012 | A1 |
20120312957 | Loney et al. | Dec 2012 | A1 |
20120320045 | Yao | Dec 2012 | A1 |
20130023007 | Zahniser et al. | Jan 2013 | A1 |
20130078668 | Levine et al. | Mar 2013 | A1 |
20130130262 | Battrell et al. | May 2013 | A1 |
20130169948 | Xie | Jul 2013 | A1 |
20130170730 | Yu et al. | Jul 2013 | A1 |
20130176551 | Wardlaw et al. | Jul 2013 | A1 |
20130177974 | Mamghani et al. | Jul 2013 | A1 |
20130203082 | Gonda et al. | Aug 2013 | A1 |
20130273968 | Rhoads et al. | Oct 2013 | A1 |
20130284924 | Mizuochi et al. | Oct 2013 | A1 |
20130290225 | Kamath et al. | Oct 2013 | A1 |
20130323757 | Poher | Dec 2013 | A1 |
20140139625 | Mathuis et al. | May 2014 | A1 |
20140139630 | Kowalevicz | May 2014 | A1 |
20140185906 | Ding et al. | Jul 2014 | A1 |
20140186859 | Calderwood et al. | Jul 2014 | A1 |
20140205176 | Obrien et al. | Jul 2014 | A1 |
20140270425 | Kenny et al. | Sep 2014 | A1 |
20140273064 | Smith et al. | Sep 2014 | A1 |
20140347459 | Greenfield et al. | Nov 2014 | A1 |
20140347463 | Lin | Nov 2014 | A1 |
20140353524 | Danuser et al. | Dec 2014 | A1 |
20150037806 | Pollak et al. | Feb 2015 | A1 |
20150124082 | Kato et al. | May 2015 | A1 |
20150183153 | Chan et al. | Jul 2015 | A1 |
20150190063 | Zakharov et al. | Jul 2015 | A1 |
20150246170 | Miao et al. | Sep 2015 | A1 |
20150278575 | Allano et al. | Oct 2015 | A1 |
20150302237 | Ohya et al. | Oct 2015 | A1 |
20150316477 | Pollak et al. | Nov 2015 | A1 |
20160042507 | Turner | Feb 2016 | A1 |
20160146750 | Hughes et al. | May 2016 | A1 |
20160168614 | Hunt | Jun 2016 | A1 |
20160187235 | Fine | Jun 2016 | A1 |
20160208306 | Pollak et al. | Jul 2016 | A1 |
20160246046 | Yorav-Raphael et al. | Aug 2016 | A1 |
20160250312 | Longley | Sep 2016 | A1 |
20160279633 | Bachelet et al. | Sep 2016 | A1 |
20170052110 | Malissek et al. | Feb 2017 | A1 |
20170115271 | Xie et al. | Apr 2017 | A1 |
20170146558 | Ishii et al. | May 2017 | A1 |
20170160185 | Minemura et al. | Jun 2017 | A1 |
20170191945 | Zhang et al. | Jul 2017 | A1 |
20170218425 | Chen et al. | Aug 2017 | A1 |
20170292905 | Obrien et al. | Oct 2017 | A1 |
20170307496 | Zahniser et al. | Oct 2017 | A1 |
20170326549 | Jones et al. | Nov 2017 | A1 |
20170328924 | Jones | Nov 2017 | A1 |
20180080885 | Ginsberg et al. | Mar 2018 | A1 |
20180246313 | Eshel et al. | Aug 2018 | A1 |
20180259318 | Yelin et al. | Sep 2018 | A1 |
20180296102 | Satish et al. | Oct 2018 | A1 |
20180297024 | Tran | Oct 2018 | A1 |
20190002950 | Pollak et al. | Jan 2019 | A1 |
20190087953 | Yorav-Raphael | Mar 2019 | A1 |
20190110718 | Brittenham | Apr 2019 | A1 |
20190130567 | Greenfield | May 2019 | A1 |
20190145963 | Zait | May 2019 | A1 |
20190266723 | Blanchard et al. | Aug 2019 | A1 |
20190302099 | Pollak | Oct 2019 | A1 |
20190347467 | Ohsaka et al. | Nov 2019 | A1 |
20200034967 | Yorav-Raphael | Jan 2020 | A1 |
20200049970 | Eshel | Feb 2020 | A1 |
20200111209 | Greenfield | Apr 2020 | A1 |
20200249458 | Eshel | Aug 2020 | A1 |
20200300750 | Eshel | Sep 2020 | A1 |
20220189016 | Barnes et al. | Jun 2022 | A1 |
Number | Date | Country |
---|---|---|
2655024 | Nov 2014 | CA |
1918501 | Feb 2007 | CN |
101403650 | Apr 2009 | CN |
101501785 | Aug 2009 | CN |
102282467 | Dec 2011 | CN |
104094118 | Oct 2014 | CN |
105556276 | Nov 2018 | CN |
0073551 | Mar 1983 | EP |
0479231 | Apr 1992 | EP |
1 381 229 | Jan 2004 | EP |
1698883 | Sep 2006 | EP |
2145684 | Jan 2010 | EP |
2 211 165 | Jul 2010 | EP |
3001174 | Mar 2016 | EP |
3123927 | Feb 2017 | EP |
3482189 | May 2019 | EP |
1 873 232 | Feb 2020 | EP |
2329014 | Mar 1999 | GB |
60-162955 | Aug 1985 | JP |
61-198204 | Sep 1986 | JP |
7-504038 | Apr 1995 | JP |
H08-313340 | Nov 1996 | JP |
9-54083 | Feb 1997 | JP |
H11-500832 | Jan 1999 | JP |
H11-73903 | Mar 1999 | JP |
2000-199845 | Jul 2000 | JP |
2002-516982 | Jun 2002 | JP |
2004-144526 | May 2004 | JP |
2004-257768 | Sep 2004 | JP |
2006-506607 | Feb 2006 | JP |
2006-301270 | Nov 2006 | JP |
2007-40814 | Feb 2007 | JP |
2009-180539 | Aug 2009 | JP |
2009-233927 | Oct 2009 | JP |
2009-268432 | Nov 2009 | JP |
2011-95225 | May 2011 | JP |
2013-515264 | May 2013 | JP |
2013-541767 | Nov 2013 | JP |
2014-41139 | Mar 2014 | JP |
2015-57600 | Mar 2015 | JP |
2016-70658 | May 2016 | JP |
2016-528506 | Sep 2016 | JP |
2017-209530 | Nov 2017 | JP |
2018-525611 | Sep 2018 | JP |
6952683 | Oct 2021 | JP |
2402006 | Oct 2010 | RU |
1985005446 | Dec 1985 | WO |
1996001438 | Jan 1996 | WO |
1996012981 | May 1996 | WO |
1996013615 | May 1996 | WO |
2000006765 | Feb 2000 | WO |
2000052195 | Sep 2000 | WO |
2000055572 | Sep 2000 | WO |
2003056327 | Jul 2003 | WO |
2003065358 | Aug 2003 | WO |
2003073365 | Sep 2003 | WO |
2003081525 | Oct 2003 | WO |
2004020112 | Mar 2004 | WO |
2004111610 | Dec 2004 | WO |
2005121863 | Dec 2005 | WO |
2006121266 | Nov 2006 | WO |
2008063135 | May 2008 | WO |
2010036827 | Apr 2010 | WO |
2010056740 | May 2010 | WO |
2010116341 | Oct 2010 | WO |
2010126903 | Nov 2010 | WO |
2010137543 | Dec 2010 | WO |
2011056658 | May 2011 | WO |
2011076413 | Jun 2011 | WO |
2011123070 | Oct 2011 | WO |
2011143075 | Nov 2011 | WO |
2012000102 | Jan 2012 | WO |
2012029269 | Mar 2012 | WO |
2012030313 | Mar 2012 | WO |
2012090198 | Jul 2012 | WO |
2012154333 | Nov 2012 | WO |
2013041951 | Mar 2013 | WO |
2013098821 | Jul 2013 | WO |
2013102076 | Jul 2013 | WO |
2014146063 | Sep 2014 | WO |
2014159620 | Oct 2014 | WO |
2014188405 | Nov 2014 | WO |
2015001553 | Jan 2015 | WO |
2015029032 | Mar 2015 | WO |
2015089632 | Jun 2015 | WO |
2016021311 | Feb 2016 | WO |
2016030897 | Mar 2016 | WO |
2016203320 | Dec 2016 | WO |
2017046799 | Mar 2017 | WO |
2017168411 | Oct 2017 | WO |
2017195205 | Nov 2017 | WO |
2017195208 | Nov 2017 | WO |
2018009920 | Jan 2018 | WO |
2018102748 | Jun 2018 | WO |
2019035084 | Feb 2019 | WO |
2019097387 | May 2019 | WO |
2019102277 | May 2019 | WO |
2019198094 | Oct 2019 | WO |
2021079305 | Apr 2021 | WO |
2021079306 | Apr 2021 | WO |
2021116962 | Jun 2021 | WO |
Entry |
---|
Sawhney, A.K., et al., “Erythrocyte Alterations Induced by Malathion in Channa punctatus (Bloch)”, Bull. Environ. Contam. Toxicol., 2000, vol. 64, pp. 395-405. |
Communication dated Mar. 20, 2023 issued by the European Patent Office in application No. 22209948.3. |
Communication dated Feb. 22, 2023 issued by the Canadian Patent Office in application No. 3,081,669. |
Communication dated Mar. 17, 2023 issued by the United States Patent and Trademark Office in U.S. Appl. No. 17/083,647. |
Communication dated Mar. 2, 2023 issued in the Canadian Patent Office in application No. 3,018,536. |
Communication dated Mar. 27, 2023 issued by the Brazilian Patent Office in application No. BR122020017765-9. |
Communication dated Mar. 27, 2023 issued by the United States Patent and Trademark Office in U.S. Appl. No. 16/763,810. |
Communication dated Mar. 3, 2023 issued by the United States Patent and Trademark Office in U.S. Appl. No. 17/082,483. |
Communication dated Mar. 3, 2022 issued by the United States Patent and Trademark Office in U.S. Appl. No. 17/063,320. |
Communication dated Mar. 7, 2023 issued by the Japanese Patent Office in application No. 2021-157849. |
Communication dated Nov. 25, 2022 issued by the United States Patent and Trademark Office in U.S. Appl. No. 17/082,483. |
Onodera, M., “Organ Derangement”, Medicina, Sep. 9, 2005, vol. 42, No. 9, pp. 1582-1584 (5 pages total). |
Notice of Allowance dated Apr. 12, 2023 issued by the United States Patent and Trademark Office in U.S. Appl. No. 16/088,321. |
Tyulina, O., et al., “Erythrocyte and plasma protein modification in alcoholism: A possible role of acctaldehyde”, Biochimica et Biophysica Acta, vol. 1762, 2006, pp. 558-563 (6 pages total). |
Takakusaki, T., “Shape Change of Red Cell Ghost and ATP”, The KITAKANTO Medical Journal, 1960, vol. 10, Issue 4, pp. 522-531 (11 pages total). |
Hirota, T., et al., “Kusanon A® Poisoning Complicated by Heinz Body Hemolytic Anemia”, Japanese Association for Acute Medicine Magazine, vol. 12, No. 12, Dec. 15, 2001, (1 page total). |
Communication dated Jun. 8, 2023, issued by the Canadian Patent Office in application No. 3,160,692. |
Communication dated Jun. 9, 2023 issued by the Canadian Patent Office in application No. 3,160,688. |
Communication dated Jun. 22, 2023 issued by the Canadian Office Action in application No. 3,160,697. |
Communication dated Jul. 3, 2023 issued by the United States Patent and Trademark Office in U.S. Appl. No. 17/568,858. |
Communication dated Jul. 12, 2023 issued by the Canadian Patent Office in application No. 3,155,820. |
Communication dated Jul. 17, 2023 issued by the Canadian Patent Office in application No. 3,155,821. |
United States Second Notice of Allowance issued Aug. 23, 2023 in U.S. Appl. No. 17/490,767. |
United States Notice of Allowance issued May 15, 2023 in U.S. Appl. No. 17/490,767. |
An Examination Report issued Aug. 16, 2023, in Australian Patent Application No. 2018369859. |
Canadian Office Action issued Aug. 25, 2023 in Application No. 3,160,702. |
United States Office Action issued May 30, 2023 in U.S. Appl. No. 17/082,615. |
A Hearing Notice issued by the Indian Patent Office on Aug. 29, 2023 for IN 201817012117. |
A Hearing Notice issued by the Indian Patent Office on Sep. 1, 2023 for IN 201817036130. |
United States Office Action issued Sep. 14, 2023 in U.S. Appl. No. 17/083,647. |
United States Office Action issued Sep. 14, 2023 in U.S. Appl. No. 17/063,320. |
Office Action dated Dec. 7, 2023 which issued during the prosecution of Canadian Application No. 3,081,669. |
A Summons to an Oral Hearing issued by the European Patent Office on Oct. 5, 2023 for Application No. 17728277.9. |
A Decision to Refuse issued on Oct. 3, 2023 for Japanese Patent Application No. 2021-157849. |
Canadian Office Action issued Oct. 13, 2023 in Application No. 2,998,829. |
United States Notice of Allowance issued Oct. 12, 2023 in U.S. Appl. No. 17/568,858. |
United States Office Action issued Oct. 17, 2023 in U.S. Appl. No. 17/082,615. |
A Hearing Notice issued by the Indian Patent Office on Nov. 9, 2023 for IN 201817040226. |
Canadian Office Action issued Dec. 19, 2023 in Application No. 3,018,536. |
An Office Action dated Dec. 21, 2023 which issued during the prosecution of Brazilian Application No. 112018 072627 3. |
United States Office Action issued Jan. 9, 2024 in U.S. Appl. No. 18/203,109. |
Notice of Allowance issued for U.S. Appl. No. 16/763,810 on Feb. 8, 2024. |
United States Office Action dated Feb. 29, 2024 in U.S. Appl. No. 17/083,647. |
Canadian Office Action dated Mar. 4, 2024 in Application No. 3022770. |
Canadian Office Action dated Jan. 12, 2023 in Application No. 3022770. |
International Search Report and Written Opinion dated Mar. 11, 2024 in Application No. PCT/IB2023/062469. |
Canadian Office Action dated Mar. 6, 2024 in Application No. 3160688. |
Canadian Office Action dated Mar. 11, 2024 in Application No. 3160692. |
United States Office Action dated Mar. 22, 2024 in U.S. Appl. No. 17/360,503. |
Canadian Office Action dated Apr. 3, 2024 in Application No. 3160697. |
Canadian Office Action dated Apr. 19, 2024 in Application No. 3155820. |
New Zealand Office Action dated Apr. 23, 2024 in Application No. 787743. |
New Zealand Office Action dated Apr. 24, 2024 in Application No. 787745. |
European Office Action dated Apr. 29, 2024 in Application No. 20800326.9. |
European Office Action dated May 6, 2024 in Application No. 20 800 325.1. |
United States Office Action dated May 7, 2024 in U.S. Appl. No. 17/770,339. |
European Office Action dated May 8, 2024 in Application No. 20828314.3. |
Kerem Delikoyun, et al., “2 Deep learning-based cellular image analysis for intelligent medical diagnosis” , De Gruyter, 2021, (4 pages) https://www.degruyter.com/document/doi/10.1515/9783110668322-002/html. |
C.Briggs, et al., “ICSH Guidelines for the evaluation of blood cell analysers including those used for differential leucocyte and reticulocyte counting”, International Journal of Laboratory Hematology, 2014, vol. 36, pp. 613-627 (15 pages). |
An Office Action dated May 16, 2024 which issued during the prosecution of U.S. Appl. No. 17/063,320. |
An Office Action dated May 29, 2024 which issued during the prosecution of Korean Application No. 10-2022-7017082. |
A Chinese Office Action dated May 9, 2024 which issued during the prosecution of Application No. 202080085933.9. |
Notice of Allowance issued for Canadian Application No. 3,155,821 on May 21, 2024. |
An Office Action dated May 29, 2024 which issued during the prosecution of Korean Application No. 10-2022-7017081. |
“Blood specimens: Microscopic Examination”, Centers for Disease Control and Prevention CDC, Diagnostic Procedures, 2009 <http://www.dpd.cdc.gov/dpdx/HTML/Frames/DiagnosticProcedures/body_dp_bloodexamin.htm>. |
Agero, U., Mesquita, L.G., Neves, B.R.A., Gazzinelli, R.T. and Mesquita, O.N., 2004. Defocusing microscopy. Microscopy research and technique, 65(3), pp. 159-165. |
Ahirwar, Neetu et al., “Advanced Image Analysis Based System for Automatic Detection and Classification of Malarial Parasite in Blood Images,” International Journal of Information Technology and Knowledge Management Jan.-Jun. 2012, vol. 5, No. 1, pp. 59-64, Serial Publications Pvt. Ltd, India. |
An International Search Report and a Written Opinion both dated Jan. 23, 2017. which issued during the prosecution of Applicant's PCT/IL2016/051025. |
An International Search Report and Written Opinion in International Application No. PCT/IB2018/058861, issued on Apr. 8, 2019. |
An International Search Report and Written Opinion, dated Aug. 30, 2017 from the International Bureau in counterpart International application No. PCT/IL2017/050526. |
An International Search Report and Written Opinion, dated Aug. 8, 2017 from the International Bureau in counterpart International application No. PCT/IL2017/050523. |
An International Search Report and Written Opinion, dated May 18, 2017 from the International Bureau in counterpart International application No. PCT/IL2017/050363. |
Anand, A., et al. “Automatic Identification of Malaria-Infected RBC with Digital Holographic Microscopy Using Correlation Algorithms.” Photonics Journal, IEEE 4.5 (2012): 1456-1464. |
Bacus, J.W., 1985. Cytometric approaches to red blood cells. Pure and Applied AL Chemistry, 57(4), pp. 593-598. |
Biéler, Sylvain et al. “Improved detection of Trypanosoma brucei by lysis of red blood cells, concentration and LED fluorescence microscopy”; Acta Tropica; vol. 121, Issue 2, Feb. 2012, pp. 135-140. |
Bravo-Zanoguera, M.E., Laris, C.A., Nguyen, L.K., Oliva, M. and Price, J.H., 2007. Dynamic autofocus for continuous-scanning time-delay-and-integration image acquisition in automated microscopy. Journal of biomedical optics, 12(3), pp. 034011-034011. |
Brenner et al., An Automated Microscope for Cytologic Research a Preliminary Evaluation, [The Journal of Histochecmistry and Cytochemistry, vol. 24, No. 1, pp. 100-111, 1976. |
Briggs, C., et al., “Continuing developments with the automated platelet count”, Blackwell Publishing Ltd, International Journal of Laboratory Hematology, Jan. 18, 2007, pp. 77-91, vol. 29 (15 pages total). |
Centers for Disease Control and Prevention. DPDx—Laboratory Identification of Parasitic Diseases of Public Health Concern <http://www.cdc.gov/dpdx/diagnosticProcedures/blood/microexam.html>, Nov. 29, 2013. |
Cervantes, Serena , Jacques Prudhomme, David Carter, Krishna G Gopi, Qian Li, Young-Tae Chang, and Karine G Le Roch, High-content live cell imaging with RNA probes: advancements in high-throughput antimalarial drug discovery, BMC Cell Biology 2009, 10:45, https://bmcmolcellbiol.biomedcentral.com/track/pdf/10.1186/1471-2121-10-45 (Jun. 10, 2009). |
Chiodini, P.L. et al., “Rapid diagnosis of malaria by fluorescence microscopy”; The Lancet, vol. 337, Issue 8741, p. 624-625, Mar. 9, 1991. |
Chong, Shau Poh, Shilpa Pant, and Nanguang Chen. “Line-scan Focal Modulation Microscopy for Rapid Imaging of Thick Biological Specimens.” SPIE/OSA/IEEE Asia Communications and Photonics. International Society for Optics and Photonics, 2011. |
Emma Eriksson et al: “Automated focusing of nuclei for time lapse experiments on single cells using holographic optical tweezers”, Optics Express , vol. 17, No. 7 , Mar. 2-4, 2009, pp. 5585-5594. |
F. Boray Tek et al. “Parasite detection and identification for automated thin blood film malaria diagnosis”; Computer Vision and Image Understanding vol. 114, Issue 1, Jan. 2010, pp. 21-32. |
Fohlen-Walter, Anne PhD, et al., “Laboratory Identification of Cryoglobulinemia From Automated Blood Cell Counts, Fresh Blood Samples, and Blood Films”, American Society for Clinical Pathology, Am J Clin Pathol, 2002, pp. 606-614, vol. 117 (9 pages total). |
Frean, John. “Microscopic Determination of Malaria Parasite Load: Role of Image Analysis.” Microscopy: Science, technology, Applications, and Education (2010): 862-866. |
Gallo, V., Skorokhod, O.A., Schwarzer, e, and Arese, P. “Simultaneous determination of phagocytosis of Plasmodium falciparum-parasitized and non-parasitized red blood cells by flow cytometry”; Malaria Journal 2012 11:428. |
Garcia, et al. “Laboratory Diagnosis of Blood-borne Parasitic Diseases; Approved Guideline”; NCCLS Documents M115-a, Jun. 2000. |
Gordon, Andrew et al. “Single-cell quantification of molecules” Nature Methods 4, Jan. 21, 2007, pp. 175-181. |
Gordon, Andrew et al. Supplementary Note to Gordon et al: “Single-cell quantification of molecules” Nature Methods, Jan. 21, 2007, pp. 1-35. |
Groen, F.C.A., et al. “A comparison of different focus functions for use in autofocus algorithms”, Cytometry, Alan Liss, New York, US vol. 6, No. 2, Mar. 1, 1985 (Mar. 1, 1985) pp. 81-91. |
Guy, Rebecca, Paul Liu, Peter Pennefather and Ian Crandall, “The use of fluorescence enhancement to improve the microscopic diagnosis of falciparum malaria”, Malaria Journal 2007 6:89, https://malariajournal.biomedcentral.com/articles/10.1186/1475-2875-6-89, (Jul. 9, 2007). |
Houri-Yafin, A., et al. “An enhanced computer vision platform for clinical diagnosis of malaria” Malaria Control and Elimination, 2016, p. 138, Vo. 5, Issue 1, omics International, India. |
Jager et al. “Five-minute Giemsa stain for rapid detection of malaria parasites in blood smears”, Tropical Doctor, Vo. 41, pp. 33-35, Jan. 2011. |
Jahanmehr,S A H et al., “Simple Technique for Fluorescence Staining of Blood Cells with Acridine Orange”, Journal of Clinical Pathology, Feb. 12, 1987, pp. 926-929 (4 pages total). |
Joanny, Fanny, Helda Jana, and Benjamin Mordmllera, “In Vitro Activity of Fluorescent Dyes against Asexual Blood Stages of Plasmodium falciparum” DOI: 10.1128/AAC.00709-12. |
Kawamoto, F. and P.F.Billingsley, “Rapid diagnosis of malaria by fluorescence microscopy”, Parasitology Today, 8.2 (1992): 69-71. |
Kawamoto,F. “Rapid diagnosis of malaria by fluorescence microscopy with light microscope and interference filter”, The Lancet, vol. 337, pp. 200-202, Jan. 26, 1991. |
Keiser, J. et al., “Acridine Orange for malaria diagnosis: its diagnostic performance, its promotion and implementation in Tanzania, and the implications for malaria control”, Annals of Tropical Medicine and parasitology, 96.7 (2002): 643-654. |
Knesel, “Roche Image Analysis Systems, Inc.”, Acta Cytologica, vol. 40, pp. 60-66, (1996). |
Kumar, Amit et al. “ Enhanced Identification of Malarial Infected Objects using Otsu Algorithm from Thin Smear Digital Images.” International Journal of Latest Research in Science and Technology vol. 1,Issue 2 :p. Nos. 159-163, Jul.-Aug. 2012). |
Le, Minh-Tam et al., “A novel semi-automatic image processing approach to determine Plasmodium falciparum parasitemia in Giemsa-stained thin blood smears”, BMC Cell Biology, published Mar. 28, 2008. |
Leif, “Methods for Preparing Sorted Cells as Monolayer Specimens”, Springer Lab Manuals, Section 7—Chapter 5 pp. 592-619, (2000). |
Life Technologies Corporation, “Counting blood cells with Countless Automated Cell Counter” found at http://www.lifetechnologies.com/content/dam/LifeTech/migration/files/cell-tissue-analysis/pdfs.par.83996.file.dat/w-082149-countless-application-blood-cells.pdf, four pages, (2009). |
Matcher, S.J., et al. “Use of the water absorption spectrum to quantify tissue chromophore concentration changes in near-infrared spectroscopy”, Physics in Medicine & Biology, vol. 39, No. 1, 1994 pp. 177-196, IOP Publishing Ltd., UK. |
Mendiratta, D.K. et al. Evaluation of different methods for diagnosis of P. falciparum malaria; Indian J Med Microbiol. Jan. 2006;24(1):49-51. |
Merchant et al. , “Computer-Assisted Microscopy”, The essential guide to image processing, Chapter 27, pp. 777-831, Academic Press, (2009). |
Moody , “Rapid Diagnostic Tests for Malaria Parasites”, Clinical Microbiology Reviews, vol. 15, No. 1, pp. 66-78, 12 (2002). |
Moon S, Lee S, Kim H, Freitas-Junior LH, Kang M, Ayong L, et al. (2013) An Image Analysis Algorithm for Malaria Parasite Stage Classification and Viability Quantification. PLoS ONE 8(4): e61812. https://doi.org/10.1371/journal.pone.0061812. |
Ortyn, William E.,et al. “Extended Depth of Field Imaging for High Speed Cell Analysis.” Cytometry Part A 71.4, 2007): 215-231. |
Osibote, O. A., et al. “Automated focusing in bright-field microscopy for tuberculosis detection”, Journal of Microscopy 240.2 (2010)pp. 155-163. |
Pasini, Erica M. et al. “A novel live-dead staining methodology to study malaria parasite viability”; Malaria Journal 2013 12:190. |
Piruska, Aigars et al., “The autofluorescence of plastic materials and chips measured under laser irradiation” Lab on a Chip, 2005, 5, 1348-1354, published Nov. 1, 2005. |
Poon et al., “Automated Image Detection and Segmentation in Blood Smears”, [Cytometry 1992 13:766-774]. |
Purwar, Yashasvi, et al. “Automated and Unsupervised Detection of Malarial Parasites in Microscopic Images.” Malaria Journal 10.1 (2011): 364. |
Rappaz, Benjamin et al., “Comparative study of human erythrocytes by digital holographic microscopy, confocal microscopy, and impedance volume analyzer” Cytometry Part A, 2008, vol. 73, Issue 10, pp. 895-903, John Wiley & Sons, US. |
Roma, P. M. S., et al . “Total three-dimensional imaging of phase objects using defocusing microscopy: Application to red blood cells.” Applied Physics Letters 104,25 (2014): 251107. |
Ross, Nichoals E., et al., “Automated image processing method for the diagnosis and classification of malaria on thin blood smears”, Medical and Biological Engineering and Computing, May 2006, vol. 44, Issue 5, pp. 427-436, Springer Publishing Company, US. |
Sheikh , H., Bin Zhu, Micheli-Tzanakou, E. (1996) “Blood cell identification using neural networks.” Proceedings of the IEEE 22nd Annual Northeast Bioengineering Conference; pp. 119-120. |
Shen, Feimo, Louis Hodgson and Klaus Hahn, “Digital autofocus method for automated microscopy”, Methods in Enzymology vol. 414, 2006, pp. 620-632. |
Shute G. T. and T. M. Sodeman, “Identification of malaria parasites by fluorescence microscopy and acridine orange staining”, Bulletin of the World Health Organ. 1973; 48(5): 591-596. |
Sun, Yu, S. Duthaler and B.J. Nelson, “Autofocusing algorithm selection in computer microscopy”, 2005 IEEE/RSJ International Conference on Intelligent Robots and Systems. |
Tek, F. Boray, Andrew G. Dempster, and Izzet Kale. “Computer Vision for Microscopy Diagnosis of Malaria.” Malaria Journal 8.1 (2009): 153. |
Thung, Ferdian, and Iping Supriana Suwardi. “Blood Parasite Identification Using Feature Based Recognition.” Electrical Engineering and Informatics (ICEEI), 2011 International Conference on. IEEE, 2011. |
U.S. Appl. No. 61/427,809, filed Dec. 29, 2010. (CAT-1). |
U.S. Appl. No. 61/870,106, filed Aug. 26, 2013. (CAT-2). |
U.S. Appl. No. 62/042,388, filed Aug. 27, 2014 (CAT-2). |
UNITAID Malaria Diagnostic Technology and Market Landscape, 2nd Edition (2014). |
Wissing, Frank et al. “Illumination of the Malaria Parasite Plasmodium falciparum Alters Intracellular pH”, Implications for Live Cell Imaging; published Jul. 24, 2002,JBS Papers in Press, vol. 277 No. 40, pp. 27747-37755. |
Wright, J H. “A Rapid Method for the Differential Staining of Blood Films and Malarial Parasites” Journal of medical research vol. 7,1 (1902): 138-44. |
Wu, Caicai et al., “Feasibility study of the spectroscopic measurement of oxyhemoglobin using whole blood without pre-treatment”, The Analyst, Mar. 1998, pp. 477-481, vol. 123 (5 pages total). |
Wu, Qiang, Fatima Mechant, and Kenneth Castleman. Microscope Image Processing. Chapter 16, Autofocusing, pp. 441-467, Academic Press, 2010. |
Xu, Lili, Asok Chaudhuri, “Plasmodium yoelii: A differential fluorescent technique using Acridine Orange to identify infected erythrocytes and reticulocytes in Duffy knockout mouse”, Experimental Parasitology, vol. 110, Issue 1, May 2005, pp. 80-87, https://www.sciencedirect.com/science/article/pii/S001448940500038X, (May 31, 2005). |
Yang, Ming, and Li Luo. “A Rapid Auto-Focus Method in Automatic Microscope.” Signal Processing, 2008. ICSP 2008. 9th International Conference on. IEEE,2008. |
Yao, LN et al. “Pathogen identification and clinical diagnosis for one case infected with Babesia”. Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi Chinese journal of parasitology parasitic diseases, Aug. 2012. |
Yazdanfar, S., Kenny, K.B., Tasimi, K., Corwin, A.D., Dixon, E.L. and Filkins, R.J., 2008. Simple and robust image-based autofocusing for digital microscopy. Optics express, 16(12), pp. 8670-8677. |
Zahniser et al., Automated Slide Preparation System for the Clinical Laboratory, Cytometry, vol. 26, No. 10, pp. 60-64, (1996). |
A European Examination Report dated Dec. 9, 2019. which issued during the prosecution of Applicant's European App No. 16782094.3. |
Notice of Allowance dated Mar. 2, 2020, which issued during the prosecution of U.S. Appl. No. 16/657,473. |
A European Examination Report dated Feb. 1, 2019. which issued during the prosecution of Applicant's European App No. 17717000.8. |
A European Examination Report dated Sep. 3, 2019. which issued during the prosecution of Applicant's European App No. 17717000.8. |
A European Examination Report dated Apr. 8, 2020. which issued during the prosecution of Applicant's European App No. 17717000.8. |
A European Examination Report dated Apr. 6, 2020. which issued during the prosecution of Applicant's European App No. 17726036.1. |
A European Examination Report dated Feb. 11, 2020. which issued during the prosecution of Applicant's European App No. 17728277.9. |
An Office Action dated Aug. 24, 2020 for U.S. Appl. No. 16/098,893. |
A Chinese Office Action and dated May 22, 2020. which issued during the prosecution of Chinese Application No. 201680053431.1. |
A Restriction Requirement issued by the USPTO on Aug. 24, 2020 for U.S. Appl. No. 16/088,321. |
Saraswat, et al. “Automated microscopic image analysis for leukocytes identification: A survey”, ABV—Indian Institute of Information Technology and Management, Gwalior, India. |
Hiremath, P.S,. et al., “Automated Identification and Classification of White Blood Cells (Leukocytes) in Digital Microscopic Images”, IJCA Special Issue on “Recent Trends in Image Processing and Pattern Recognition” RTIPPR, 2010. |
Witt, et al. “Establishing traceability of photometric absorbance values for accurate measurements of the haemoglobin concentration in blood.”,Metrologia 50 (2013) 539-548. |
Putzu, et al., “Leucocyte classification for leukaemia detection using image processing techniques.”, Artificial Intelligence in Medicine, vol. 63, No. 3, Nov. 1, 2014. |
Varga, et al., “An automated scoring procedure for the micronucleus test by image analysis,”, Mutagenesis vol. 19 No. 5 pp. 391-397, 2004. |
Ran, Qiong et al. “Spatial-spectral blood cell classification with microscopic hyperspectral imagery” Proc. SPIE 10461, AOPC 2017: Optical Spectroscopy and Imaging, 1046102 (Oct. 24, 2017). |
Omucheni et al. “Application of principal component analysis to multispectral-multimodal optical image analysis for malaria diagnostics”, Malaria Journal 2014, 13:485 http://www.malariajournal.com/content/13/1/485. |
Ben-Suliman-2018-Computerized Counting-Based System for Acute Lymphoblastic Leukemia Detection in Microscopic Blood Images: 27th International Conference on Artificial Neural Networks, Rhodes, Greece, Oct. 4-7, 2018, Proceedings, Part II. |
An Office Action dated Dec. 8, 2020 for Japanese Patent Application No. 2018/512961. |
An Examination Report issued on Dec. 7, 2020 for Australian Patent Application No. 2016322966. |
An Office Action dated Jan. 11, 2021 for U.S. Appl. No. 16/098,893. |
An Examination Report issued on Apr. 29, 2021 for Australian Patent Application No. 2016322966. |
International Search Report issued for PCT Application No. PCT/IB2020/059924 on Mar. 22, 2021. |
International Search Report issued for PCT Application No. PCT/IB2020/059925 on Mar. 26, 2021. |
Invitation to pay fees and Partial Search Report issued for PCT Application No. PCT/IB2020/059924 on Jan. 28, 2021. |
Invitation to pay fees and Partial Search Report issued for PCT Application No. PCT/IB2020/059925 on Feb. 4, 2021. |
A Japanese Office Action dated Mar. 30, 2021. which issued during the prosecution of Application No. 2018/558180. |
An Office Action dated Mar. 9, 2021 for U.S. Appl. No. 16/088,321. |
An Office Action dated Jan. 29, 2021 for U.S. Appl. No. 16/099,270. |
Bovik, Alan C., et. “The Essential Guide to Image Processing”, Chapter 27, “Computer Assisted Microscopy”,pp. 777-831; Academic Press, 2009 (Merchant). |
Communication dated Nov. 18, 2014 from the Canadian Patent Office in application No. 2,655,024. |
Laboratory diagnosis of blood-borne parasitic diseases: approved guideline, 2000—NCCLS (CAT-1). |
Price Jeffrey H. and David A. Gough, “Comparison of phase-contrast and fluorescence digital autofocus for scanning microscopy”, Cytometry 16.4 (1994) 283-297. |
Vink, J.P. et al., “An automatic vision-based malaria diagnosis system”, Journal of Microscopy 250.3 (2013):166-178. |
An International Search Report and Written Opinion for Application No. PCT/IB2020/061731 issued on Feb. 22, 2021. |
Invitation to pay fees and Partial Search Report issued for PCT Application No. PCT/IB2020/061732 on Mar. 10, 2021. |
Invitation to pay fees and Partial Search Report issued for PCT Application No. PCT/IB2020/061736 on Mar. 12, 2021. |
Invitation to pay fees and Partial Search Report issued for PCT Application No. PCT/IB2020/061728 on Mar. 15, 2021. |
International Search Report issued for PCT Application No. PCT/IB2020/061724 on Mar. 10, 2021. |
An International Search Report and Written Opinion for PCT Application No. PCT/IB2020/061732 mailed on May 7, 2021. |
International Search Report and Written Opinion for PCT Application No. PCT/IB2020/061728 mailed on May 7, 2021. |
International Search Report and Written Opinion for PCT Application No. PCT/IB2020/061736 mailed on May 3, 2021. |
Non-Final Office Action dated Jun. 17, 2021 which issued during the prosecution of U.S. Appl. No. 16/851,410. |
A Final Office Action dated Jun. 17, 2021 which issued during the prosecution of U.S. Appl. No. 16/088,321. |
Notice of Allowance dated May 19, 2021 which issued during the prosecution of U.S. Appl. No. 16/099,270. |
A Restriction Requirement issued by the USPTO on Oct. 19, 2020 for U.S. Appl. No. 16/099,270. |
An Extended European Search Report issued for European Patent Application No. 21164814.2 on Jun. 9, 2021. |
Third Office Action dated Jul. 12, 2021 which issued during the prosecution of Chinese Patent Application No. 201680053431.1. |
Non-Final Office Action dated Jul. 27, 2021, which issued during the prosecution of U.S. Appl. No. 16/851,686. |
Non-Final Office Action dated Aug. 19, 2021, which issued during the prosecution of U.S. Appl. No. 16/098,893. |
Non-Final Office Action dated Sep. 1, 2021 which issued during the prosecution of U.S. Appl. No. 16/088,321. |
First Office Action dated Aug. 4, 2021 which issued during the prosecution of Chinese Patent Application No. 201780027908.3. |
An Examination Report dated Mar. 4, 2021 which issued during the prosecution of Indian Patent Application No. 201817036130. |
An Examination Report dated May 5, 2021 which issued during the prosecution of Indian Patent Application No. 201817012117. |
Non-Final Office Action dated Oct. 6, 2021, which issued during the prosecution of U.S. Appl. No. 17/063,320. |
Notice of Allowance dated Aug. 3, 2021, which issued during the prosecution of U.S. Appl. No. 16/851,410. |
Notice of Allowance dated Nov. 5, 2021, which issued during the prosecution of U.S. Appl. No. 16/851,410. |
Notice of Allowance dated Nov. 10, 2021, which issued during the prosecution of U.S. Appl. No. 16/851,686. |
Supplemental Notice of Allowance dated Nov. 12, 2021, which issued during the prosecution of U.S. Appl. No. 16/851,686. |
A European Examination Report issued for European Patent Application No. 17728277.9 on Dec. 23, 2021. |
Notice of Allowance dated Jan. 21, 2022, which issued during the prosecution of U.S. Appl. No. 16/098,893. |
An Office Action dated Feb. 16, 2022 which issued during the prosecution of U.S. Appl. No. 16/088,321. |
An Office Action dated May 6, 2022 which issued during the prosecution of U.S. Appl. No. 16/763,810. |
A Non-Final Office Action dated May 26, 2022 which issued during the prosecution of U.S. Appl. No. 17/083,775. |
An Office Action dated May 31, 2022 which issued during the prosecution of U.S. Appl. No. 17/083,659. |
Examination Report issued by the Indian Patent Office on Jun. 28, 2022 in Indian Patent Application No. 202047019700. |
A Japanese Office Action dated Jul. 1, 2024 which issued during the prosecution of Application No. 2022-521112. |
A Japanese Office Action dated Jul. 3, 2024 which issued during the prosecution of Application No. 2022-521238. |
Non-Final Office Action dated Jul. 8, 2024 which issued during the prosecution of U.S. Appl. No. 18/397,324. |
Notice of Allowance issued for U.S. Appl. No. 18/203,109 on Jun. 13, 2024. |
A Chinese Office Action dated May 23, 2024, which issued during the prosecution of Application No. 202080073583.4. |
A Chinese Office Action dated May 23, 2024, which issued during the prosecution of Application No. 202080073623.5. |
An Office Action dated Jul. 12, 2022, which issued during the prosecution of U.S. Appl. No. 16/088,321. |
An Office Action dated Aug. 2, 2022, which issued during the prosecution of Japanese Patent Application No. 2021-145455. |
An Examination Report dated Aug. 25, 2022, which issued during the prosecution of Australian Patent Application No. 2017263807. |
An Office Action dated Aug. 30, 2022 which issued during the prosecution of Japanese Patent Application No. 2020-526176. |
An Office Action dated Sep. 13, 2022 which issued during the prosecution of Japanese Patent Application No. 2021-157849. |
Hideto Miura, “How to regard as how to consider the poikilocyte in urine an erroneous decision factor”, Modern Medical Laboratory, Sep. 1, 2002, vol. 30, No. 9, pp. 862-864 (6 pages total). |
Jun Hashimoto, “Morphological Studies of Urinary Red Blood Cells in Renal and Urinary Tract Disorders (II) Use of Wright's Stain in Differential Diagnosis between Renal and Urinary Tract Disorders” Kawasaki Medical Congress Magazine, Mar. 1989, vol. 15, No. 1, pp. 94-101 (9 pages total). |
D F Birch et al., “The research on the differential diagnosis of the kidney urinary tract obstacle by glomerular or non-glomerular”, Lancet, Oct. 20, 1979, vol. 2, No. 8147, pp. 845-846 (3 pages total). |
A First Examination Report dated Sep. 19, 2022, which issued during the prosecution of Indian Patent Application No. 201817040226. |
An Office Action dated Oct. 3, 2022 which issued during the prosecution of U.S. Appl. No. 16/763,810. |
An Office Action dated Oct. 25, 2022 which issued during the prosecution of Canadian Application No. 2,998,829. |
An Office Action dated Oct. 5, 2022 which issued during the prosecution of Brazilian Application No. 112018005099-7. |
An Office Action dated Nov. 25, 2022 which issued during the prosecution of Brazilian Application No. 122020017765-9. |
An Office Action dated Dec. 9, 2022 which issued during the prosecution of United States U.S. Appl. No. 17/083,647. |
An Office Action dated Dec. 28, 2022 which issued during the prosecution of Russian Patent Application No. 2022112399. |
An Office Action dated Dec. 28, 2022 which issued during the prosecution of Russian Patent Application No. 2022112393. |
An Office Action dated Jan. 6, 2023 which issued during the prosecution of U.S. Appl. No. 17/063,320. |
An Office Action dated Sep. 2, 2022 which issued during the prosecution of U.S. Appl. No. 17/063,320. |
An Office Action dated Jan. 5, 2023 which issued during the prosecution of Chinese Patent Application No. 201880079888.9. |
An Examination Report dated Jan. 23, 2023, which issued during the prosecution of Australian Patent Application No. 2022200112. |
An Office Action dated Jan. 19, 2023 which issued during the prosecution of U.S. Appl. No. 17/490,767. |
A Japanese Office of Action dated Nov. 5, 2024, which issued during the prosecution of JP Application No. 2022-534369. |
Number | Date | Country | |
---|---|---|---|
20230028360 A1 | Jan 2023 | US |
Number | Date | Country | |
---|---|---|---|
62946988 | Dec 2019 | US |